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PERSPECTIVE

The Clock Is Ticking: Countdown to
Metastases
Linda D. Siracusa1*, Karen M. Bussard2*
1 Department of Microbiology and Immunology, Sidney Kimmel Cancer Center, Thomas Jefferson
University, Philadelphia, Pennsylvania, United States of America, 2 Department of Cancer Biology, Sidney
Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania, United States of America
* Linda.Siracusa@jefferson.edu (LDS); Karen.Bussard@jefferson.edu (KMB)

Metastases cause more than 90% of the morbidity and mortality associated with human cancers. Gene expression signatures associated with cancer progression and metastasis serve as
unique tools to assist in patient diagnosis, prognosis, and treatment. Various types of signatures
have been identified, ranging from those that are tumor-intrinsic or specific to a particular cancer subtype [1] to genes associated with a specific clinical outcome (e.g., “poor prognosis gene
signature”) [2], as well as to genes associated with the development of metastatic lesions [3]. Of
those genes that drive cancer processes, some may function by acting on the primary tumor—
causing rise of metastatic lesions—or at the metastatic site to promote colonization, survival,
and incorporation of surrounding stroma. Identification of metastasis susceptibility genes is
thus key for prediction of cancer risk and metastatic relapse.
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A Mouse Model for Breast Cancer Tumorigenesis
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The process of metastasis is complex, and debate has ensued concerning the role of host gene
variation in contributing to metastatic potential. Although evaluation and sequencing of
human tumors is revealing insights, much work still needs to be done to achieve the goal of
personalized medicine, in which sequence variants dictate a patient’s course of treatment. To
understand how genetic background influences primary cancer development and subsequent
metastases, Hunter and colleagues chose an elegant model system [4]—namely, a transgenic
mouse in which the polyoma virus middle T antigen is under the control of the mouse mammary tumor virus (MMTV-PyMT) promoter on the FVB/NJ inbred strain background.
MMTV-PyMT mice develop mammary cancers that metastasize to the lung [5].
Using the MMTV-PyMT mice, Hunter and colleagues screened inbred strains to identify
those that were susceptible or resistant to mammary tumor growth and metastases. By comparing the PAM50 gene signatures of primary mammary tumors, they demonstrated that tumor
subtype is significantly impacted by the host genome [6]. Crossing MMTV-PyMT males with
females from the genetically divergent MOLF/EiJ inbred strain, followed by crossing hybrid
MMTV-PyMT males to FVB/NJ females, predisposed MMTV-PyMT N2 offspring to mammary tumors with gene signatures resembling estrogen receptor negative (ER-) breast cancers,
thus tilting the model towards an aggressive form of breast cancer [6]. In this issue, the authors
use quantitative trait loci (QTL) analyses to identify a region on mouse chromosome 6 that
contains candidate genes for lung metastasis, including the Aryl hydrocarbon receptor nuclear
translocator (Arntl2) gene (a member of the circadian clock; the Arntl2 gene has also been
called Bmal2, Mop9, and bHLHe6). Using an Arntl2 knockout mouse, the authors demonstrate
that absence of Arntl2 increases the number of lung metastases but not metastatic latency or
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Fig 1. Identification of the Arntl2 gene and its relationship to cancer metastases. The clock represents
circadian rhythms. The external double arrows indicate how genetic studies using mouse models inform
studies of human cancer, leading to the discovery of polymorphisms in the Arntl2 gene that influence
mammary cancer metastases to the lungs [7]. Black dots on the lung diagram represent metastatic lesions.
doi:10.1371/journal.pgen.1006299.g001

burden. Furthermore, the authors use CRISPR/Cas9 gene editing to recapitulate specific FVB/
NJ polymorphisms in the MOLF/EiJ genetic background and show that sequence variants in
the promoter region of Arntl2 alter transcript levels, leading to changes in the metastatic potential of primary mammary tumors ([7]; this issue). Finally, they translate these findings to
human cancers by evaluating sequence variants affecting ARNTL2 expression and their impact
on disease-free survival. This study demonstrates the power of mammalian model systems coupled with unbiased screens to identify understudied genes, test hypotheses using gene editing
technology, and decipher mechanisms involved in metastatic spread (Fig 1).

The Arntl2 Gene Acts in a Tumor Cell–Autonomous Manner
The discovery of Arntl2 was based on its sequence similarity to the Arntl and Drosophila Cycle
(cyc) genes; Arntl2 arose following duplication and divergence of the Arntl gene in vertebrates
(the Arntl gene has also been called Bmal1, Mop3, and bHLHe5) and is linked to modulation of
circadian rhythms [8]. Interestingly, Ha et al. established that alteration of Arntl2 solely
impacts cells of the tumor, with no impact on supporting stromal cells [7]; when hybrid Arntl2
knockout mice were compared with wildtype Arntl2 mice after orthotopic injection of syngeneic 4T1 mammary cells, there were no differences in the number of lung metastases, suggesting that Arntl2 acts in a tumor cell–autonomous manner. Similar studies by Hunter and
colleagues indicate that these properties are gene-specific, with other metastasis susceptibility
genes (specifically Cadm1) impacting signaling and subsequent tumor progression in CD8+ T
lymphocytes [9].
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Most recently, Brady et al. showed a supportive role for Arntl2 in driving lung adenocarcinoma and subsequent metastatic outgrowths [10]. ARNTL2 expression was also shown to be
up-regulated in colorectal cancers and correlated with tumor invasiveness [11]. Importantly,
the relationship of ARNTL2 to lung metastases may not be limited to breast cancer, as its paralog, the ARNTL gene, has been implicated in colorectal, hepatic, and other cancers [12,13].

Specificity of Metastasis Susceptibility Genes to Tumor Subtype
It is now accepted that a family history of cancer correlates with increased risk and potential
development of metastatic lesions. With the discovery of high-risk penetrant mutations in
the BRCA1 and BRCA2 genes, it became evident that some breast cancers are inherited diseases [14,15]. Hunter and colleagues previously used the MMTV-PyMT mouse model to
identify genes that influence metastatic progression [9,16]; however, these prior studies identified genes influencing metastasis of ER+ breast tumors, such as the RRP1B and SIPA1 genes
[17]. Their current study illustrates a link between metastasis susceptibility genes and breast
cancer subtypes.

Future Prospects
The current challenge is to identify genes and/or sequence variants predisposing individuals
to cancer metastases. While in vitro assays allow for the investigation of proliferation, motility, and invasion, and in vivo models illustrate specific portions of the metastatic cascade,
both systems do not fully recapitulate human cancer progression and the metastatic microenvironment. The vast genetic diversity present in inbred mouse strains, coupled with the ability to produce novel genetically engineered alleles with surgical precision, provide for
mammalian model systems that closely mimic human cancer subtypes and enable identification of genes associated with inherited metastasis susceptibility. The report by Ha et al.
describes a clever mating scheme that converted a predominantly ER+, luminal phenotype
into a system that more closely resembles ER- tumors. Similarly, Lee et al. recently utilized
QTL analysis of (TRAMP x PWK/PhJ)F2 mice to identify two novel candidate genes for
prostate cancer metastasis susceptibility [18]. These types of studies illustrate the importance
of designing creative model systems capable of recapitulating early stages of cancer development through progression and metastases to answer provocative questions pertaining to
human disease.
Data collected from mammalian models, in concert with data generated by profiling human
tissues, will facilitate the development of algorithms useful for predicting an individual’s specific risk of cancer and/or metastatic relapse, given their personalized gene signature. More
importantly, the interchange of information between these systems may help solve important
questions such as:
• Are there specific genes that govern whether and how long disseminated tumor cells of a
given cancer type remain in a quiescent state?
• Are there specific metastatic genes that cause dormant cancer cell reawakening?
• Of the cancers that preferentially metastasize to the same organ, are there common genes
causing directional metastasis?
Mammalian model systems are perfectly poised to test these and other questions, including
ones regarding the emerging associations between dysregulation of clock genes and cancer
(reviewed in [19]). Further intriguing issues revolve around the timing of cancer treatments,
which may be adjusted to each patient’s circadian rhythms to result in better outcomes
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(reviewed in [20]). The answers will enhance our understanding of metastases as well as provide for better clinical management and development of preventive strategies.
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